0000905718-17-000755.txt : 20170811 0000905718-17-000755.hdr.sgml : 20170811 20170811170317 ACCESSION NUMBER: 0000905718-17-000755 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170713 FILED AS OF DATE: 20170811 DATE AS OF CHANGE: 20170811 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: EMSTER KURT VON CENTRAL INDEX KEY: 0001252524 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-37923 FILM NUMBER: 171025907 MAIL ADDRESS: STREET 1: 601 GATEWAY BOULEVARD STREET 2: SUITE 350 CITY: SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CRISPR Therapeutics AG CENTRAL INDEX KEY: 0001674416 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 473173478 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: BAARERSTRASSE 14 CITY: ZUG STATE: V8 ZIP: CH-6300 BUSINESS PHONE: 6173154600 MAIL ADDRESS: STREET 1: BAARERSTRASSE 14 CITY: ZUG STATE: V8 ZIP: CH-6300 4/A 1 vonemster_fm4amaug112017.xml OWNERSHIP DOCUMENT X0306 4/A 2017-07-13 2017-07-17 0 0001674416 CRISPR Therapeutics AG CRSP 0001252524 EMSTER KURT VON C/O CRISPR THERAPEUTICS, INC. 200 SIDNEY STREET CAMBRIDGE MA 02139 1 0 0 0 Common Shares 2173000 I See Footnote This amendment is being filed to correct the amount of securities beneficially owned following the reported transactions. The total amount of securities beneficially owned was misstated on Kurt von Emster's (the "Reporting Person") original Form 4 filed with the Securities and Exchange Commission on July 17, 2017, and on five Form 4s filed by the Reporting Person after such date through the date of this amendment. These shares are held by Abingworth Bioventures VI, LP ("Abingworth"). Abingworth Bioventures VI GP LP ("Abingworth GP") serves as the general partner of Abingworth. Abingworth General Partner VI LLP, serves as the general partner of Abingworth GP. Abingworth (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VI LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by Abingworth. The Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. /s/ John Heard, as attorney-in-fact 2017-08-11